Resource for Molecular Imaging Agents in Precision Medicine

精准医学分子成像剂资源

• 批准号: 10226206
• 负责人: MARTIN G POMPER
• 金额: $ 117.95万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-15 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10226206
• 关键词: Address; Autologous Transplantation; Biological; Biological Markers; Biomedical Technology; Brain imaging; CAR T cell therapy; Cancer Vaccines; Caring; Cell Line; Cell Transplantation; Cell surface; Cells; Chemical Agents; Chemicals; Chemistry; Clinic; Clinical; Collaborations; Communities; Data; Detection; Development; Discipline of Nuclear Medicine; Education; Environment; FOLH1 gene; Generations; Genetic; Genetically Engineered Mouse; Goals; Grant; Hand; Histopathology; Human; Image; Immersion; Immunity; Immunohistochemistry; Immunooncology; Immunotherapy; Industry; Inflammation; Inflammatory; Infrastructure; Institutes; Investments; Journals; Libraries; Link; Location; Malignant Neoplasms; Medical; Methods; Mission; Molecular Genetics; National Institute of Biomedical Imaging and Bioengineering; New Agents; Organic Synthesis; Patient Care; Patients; Peptides; Peptoids; Pharmacology; Phenotype; Positron-Emission Tomography; Preclinical Testing; Process; Radiology Specialty; Reagent; Recording of previous events; Reporter; Research; Resources; Schools; Services; Site; System; Technical Expertise; Technology; Training; Transgenic Organisms; Translating; Translations; United States National Institutes of Health; Universities; Validation; Work; anticancer research; arm; cancer cell; cancer imaging; cancer immunotherapy; cellular imaging; commercialization; cost; design; flexibility; handicapping condition; human imaging; imaging agent; imaging modality; imaging system; immune checkpoint; in vitro Model; in vivo; in vivo monitoring; instrumentation; lectures; molecular imaging; neuroinflammation; next generation; nuclear division; phase II trial; pre-clinical; precision medicine; programs; radioligand; radiotracer; research and development; side effect; small molecule; targeted agent; technology development; theranostics; tumor; tumor microenvironment; web site

OVERALL RESOURCE: Summary The Resource for Molecular Imaging Agents in Precision Medicine is a program spanning three campuses of the Johns Hopkins University (JHU). In our view precision medicine is using all data at hand regarding a particular patient to enable the best possible care for that patient. We believe that carefully designed molecular imaging agents can contribute to this. We are now poised to offer a unique Biomedical Technology Resource Center (BTRC) with a heavy emphasis on the provision of chemistry – new reagents, methods and training in their development and practice – for molecular imaging. The biological theme of the BTRC is relationships between cancer, inflammation and immunity, deeper study of which is an unmet need. Although brilliant research continues worldwide in the development of new molecular imaging agents, few have had actual impact on addressing human infirmity and many do not justify the cost of their development. In March 2014 the NIBIB conducted a study “to better understand the reasons why more molecular imaging agents and instrumentation developed with NIH grant support are not being translated to the clinic nor subsequently commercialized.” To address those shortcomings, the JHU BTRC will be highly translational by leveraging the Center for Translational Molecular Imaging (CTMI) at the Johns Hopkins Bayview medical campus, the F. M. Kirby Center for Functional Brain Imaging at the Kennedy Krieger Institute, the Division of Cancer Imaging Research, and the Division of Nuclear Medicine and Molecular Imaging, all of which are highly integrated into numerous departments and schools at JHU. We have generated agents that have been licensed and are in the process of commercialization. However to date those activities have been performed on an ad hoc basis, and we intend to expand upon them in two new ways: (1) provide targeted and unique technical research and development (TR&D) projects that will (2) enable widespread dissemination and training in their use, enhancing the capacity of the centers and divisions noted above to perform their intended functions – discovery with intent to educate, promote new collaborative, transdisciplinary research and to manage a variety of conditions, while addressing unanticipated effects of emerging cancer immunotherapies. The unique aspect of the BTRC is its focus on provision of new, precision materials, to test these pre-clinically and progress them to human use, delivered on-site or to our collaborators in a format suitable for their implementation. We will assure proper off-site utilization through continual, reciprocal education and “push-pull” interactions. The program is agnostic to imaging modality and composition of the materials to provide, relying upon the specific expertise within each TR&D. In addition to sharing the goal of leveraging chemistry for imaging, the four TR&Ds will be linked through the aforementioned biological theme. They can briefly be summarized as focusing on new theranostics (TR&D 1), molecular-genetic imaging systems (TR&D 2), agents for probing immunity (TR&D 3), and targeted agents for chemical exchange saturation transfer (CEST, TR&D 4). Within TR&Ds 1 and 3 are also the Pre-clinical and Clinical Validation cores, respectively.

总体资源：摘要

项目成果

Acoustic-resolution photoacoustic microscope based on compact and low-cost delta configuration actuator.

• DOI: 10.1016/j.ultras.2021.106549
• 发表时间: 2022-01
• 期刊: Ultrasonics
• 影响因子: 4.2
• 作者: Gao S;Tsumura R;Vang DP;Bisland K;Xu K;Tsunoi Y;Zhang HK
• 通讯作者: Zhang HK

Carbon Dots as a New Class of Diamagnetic Chemical Exchange Saturation Transfer (diaCEST) MRI Contrast Agents.

• DOI: 10.1002/anie.201904722
• 发表时间: 2019-06
• 期刊: Angewandte Chemie
• 作者: Jia Zhang;Yue Yuan;Minling Gao;Zheng Han;Chengyan Chu;Yuguo Li;P. V. van Zijl;M. Ying;J. Bulte;Guanshu Liu

A Unique Core-Shell Structured, Glycol Chitosan-Based Nanoparticle Achieves Cancer-Selective Gene Delivery with Reduced Off-Target Effects.

• DOI: 10.3390/pharmaceutics14020373
• 发表时间: 2022-02-07
• 期刊: Pharmaceutics
• 影响因子: 5.4
• 作者: Cheng B;Ahn HH;Nam H;Jiang Z;Gao FJ;Minn I;Pomper MG
• 通讯作者: Pomper MG

6-O-(2-[18F]Fluoroethyl)-6-O-Desmethyl-Diprenorphine ([18F]FE-DPN) Preferentially Binds to Mu Opioid Receptors In Vivo.

6-O-(2-[18F]氟乙基)-6-O-去甲基-二丙诺啡 ([18F]FE-DPN) 在体内优先与 Mu 阿片受体结合。

• DOI: 10.1007/s11307-022-01767-5
• 发表时间: 2023
• 期刊: Molecular imaging and biology
• 影响因子: 3.1
• 作者: Levinstein,MarjorieR;Ventriglia,EmilyaN;Gomez,JuanL;Budinich,ReeceC;Marton,János;Henriksen,Gjermund;Holt,DanielP;Dannals,RobertF;Pomper,MartinG;ZarateJr,CarlosA;Bonaventura,Jordi;Michaelides,Michael
• 通讯作者: Michaelides,Michael

Noninvasive assessment of renal dynamics and pH in a unilateral ureter obstruction model using DCE MR-CEST urography.

• DOI: 10.1002/mrm.29436
• 发表时间: 2023-01
• 期刊: Magnetic resonance in medicine
• 影响因子: 3.3